We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
The decision to start the "rolling review" of the vaccine, Vidprevtyn, was based on preliminary results from lab studies and early-stage clinical trials in adults, the European Medicines Agency (EMA) said.